On December 22, 2023, Immunome, Inc. and Corleen Roche agreed to a mutual separation effective January 2, 2024 (Roche Separation Date). Effective as of the Roche Separation Date, Ms. Roche will no longer serve as the Company?s Chief Financial Officer, principal financial officer or principal accounting officer. Additionally, Ms. Roche will provide the Company with transition consulting services (Consulting Services) from the Roche Separation Date through April 5, 2024, unless earlier terminated, pursuant to the terms of a consulting agreement.

The Company?s board of directors has, effective as of the Roche Separation Date, appointed Max Rosett, in addition to his other titles, as the Company?s Interim Chief Financial Officer and principal financial officer. Mr. Rosett, age 34, has served as the Company?s Senior Vice President, Operations since October 2023. Before joining the Company, Mr. Rosett held positions of increasing responsibility with Morphimmune from January 2022 until October 2023, last serving as Morphimmune?s Acting Chief Operating Officer from March 2022 until October 2023.

Mr. Rosett also served as Principal at Research Bridge Partners, a life science investment firm, from March 2021 until October 2023. He was previously Director of Data Science at Research Bridge Partners from February 2018 to February 2021. He has also worked as an engineer at Google, and he started his career at the Boston Consulting Group, where he served clients in the pharmaceutical industry.

Mr. Rosett earned a M.S. in Computer Science from Georgia Institute of Technology and a B.A. in Mathematics from Yale University.